🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's negotiated accords with Donald Trump are "fundamentally unstable." This follows revelations that a much-touted deal on medicines, which promises zero tariffs in exchange for the NHS facing higher prices, lacks any detailed agreement beyond vague headline terms outlined by government press releases.

An Agreement in Principle Only

The deal on drug tariffs, hailed as a "generational" achievement, remains an "agreement in principle" without a signed legal text. Observers point out that the official announcements from the UK and US governments describe the deal in markedly contrasting terms. The British version emphasizes securing "zero per cent tariffs" as a unique achievement, while the American announcement dwells on the commitment for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has agreed to terms to increase medicine costs in return for nothing more than a verbal promise from President Trump," said David Henig, a trade expert. "History shows he has form for not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Concerns have been intensified by Washington's move to suspend the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US pointed to a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

Additionally, concessions secured for British farmers as part of an earlier tariff deal have yet to be formally signed off by the US, despite a looming January deadline. "We have been informed that that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have voiced worries that the government's US-UK accords are flimsy and unreliable. One minister reportedly said the series of agreements as "built on sand," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "What is even more astonishing than the US approach is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is of vital importance."

Government Downplays Risks, Points to Gains

Officials have downplayed the chances of the US backing out of the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it more concrete than the paused tech deal.

Officials admit that instability is a feature of dealing with the current US leadership. However, they argue that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "The fact we have 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

However, issues have surfaced in enacting the initial US-UK accord. Promised access for British beef have yet to be finalized, and the pledge to "remove tariffs on British steel and aluminium" has remains unmet, with tariffs remaining at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.